Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

被引：36

作者：

Lee, Sung Won ^{[1
,2
]}

Choi, Jonggi ^{[3
]}

Kim, Seung Up ^{[4
,5
]}

Lim, Young-Suk ^{[3
]}

机构：

[1] Catholic Univ Korea, Coll Med, Dept Internal Med, Seoul, South Korea

[2] Catholic Univ, Liver Res Ctr, Seoul, South Korea

[3] Univ Ulsan, Liver Ctr, Asan Med Ctr, Dept Gastroenterol,Coll Med, Seoul, South Korea

[4] Yonsei Univ, Inst Gastroenterol, Dept Internal Med, Coll Med, Seoul, South Korea

[5] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea

来源：

CLINICAL AND MOLECULAR HEPATOLOGY | 2021年 / 27卷 / 03期

关键词：

Entecavir; Tenofovir; Hepatitis B; Carcinoma; Hepatocellular; Efficacy; Outcome; DISOPROXIL FUMARATE; RISK; CIRRHOSIS;

D O I：

10.3350/cmh.2021.0179

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediate-term efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.

引用

页码：402 / 412

页数：11

共 50 条

[21] Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B One of These Things Is Not Like the Other
Flemming, Jennifer A.
Terrault, Norah A.
JAMA ONCOLOGY, 2019, 5 (01) : 17 - 18
[22] No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis
Yuan, Jie
Peng, Yang
Hao, Fa-Bao
Wang, Ya-Qin
Wang, Chun-Rui
Zhong, Guo-Chao
AGING-US, 2021, 13 (05): : 7147 - 7165
[23] Tenofovir disoproxil fumarate is not associated with a lower risk of hepatocellular carcinoma compared to entecavir in patients with chronic hepatitis B
Lee, Hye Won
Kim, Seung Up
HEPATOMA RESEARCH, 2022, 8
[24] Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir
Ridruejo, Ezequiel
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (23) : 7169 - 7180
[25] Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta-analysis
Giri, Suprabhat
Agrawal, Dhiraj
Afzalpurkar, Shivaraj
Gopan, Amrit
Angadi, Sumaswi
Sundaram, Sridhar
JOURNAL OF VIRAL HEPATITIS, 2023, 30 (02) : 108 - 115
[26] Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir
Pan, C. Q.
Hu, K. -Q.
Yu, A. S.
Chen, W.
Bunchorntavakul, C.
Reddy, K. R.
JOURNAL OF VIRAL HEPATITIS, 2012, 19 (03) : 213 - 219
[27] Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?
van Erpecum, Karel J.
Sonneveld, Milan J.
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 89 : 27 - 29
[28] Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis
Yuan, Bao-Hong
Li, Ru-Hong
Huo, Rong-Rui
Li, Min-Jun
Papatheodoridis, George
Zhong, Jian-Hong
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (05) : 782 - 794
[29] Entecavir and tenofovir on renal function in patients with hepatitis B virus-related hepatocellular carcinoma
Jeon, Mi Young
Lee, Jae Seung
Lee, Hye Won
Kim, Beom Kyung
Park, Jun Yong
Kim, Do Young
Han, Kwang-Hyub
Ahn, Sang Hoon
Kim, Seung Up
JOURNAL OF VIRAL HEPATITIS, 2020, 27 (09) : 932 - 940
[30] Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B
Tang, Kaiyue
Cheng, Huizhen
Wang, Haiyan
Guo, Yueping
MEDICINE, 2023, 102 (06) : E32894

← 1 2 3 4 5 →